Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ETNEW YORK, April...
Clinical Trial
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Medigene AG reports Financial Results and Business Update for Q1 2024
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on...
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for...
Belite Bio Announces $25 Million Registered Direct Offering
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage...
Combined General Meeting of May 16, 2024
Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for...
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE...
Y-mAbs to Present at 2024 ASCO Annual Meeting
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use...
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir...
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also...
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product...
PRUVN Reveals Human Clinical Trial Results of Max International’s RiboCeine™ Supplementation’s Impact on Serum Glutathione Levels
Findings showed that RiboCeine supplementation elevates serum glutathione levels, with more pronounced effects in older participants LOS ANGELES, April 25,...
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on...
AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029
USA News Group Commentary VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI)...
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company...
CliniOps Awarded Patent for an Innovative Offline/Online eSource, or Direct Data Collection (DDC) System, for Global Clinical Trials
Custom-Built Platform to Support Clinical Trials (CTs) Across Africa and Low & Middle Income Countries (LMIC)FREMONT, CA / ACCESSWIRE /...
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Namilumab is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine believed to play a...
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer
NEW YORK--(BUSINESS WIRE)--#biotech--Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in...
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),...